20.10.2010 • News

BASF Expects Record Year in 2010

BASF Expects Record Year in 2010

BASF has announced first figures for the third quarter of 2010 and raised its outlook for the full year. Compared with the same quarter of the previous year, third-quarter sales increased 23% to €15.8 billion, EBIT before special items rose 77% to €2.2 billion and EBIT increased 122% to €2.15 billion.The figures are at the same high level of the second quarter of 2010.

Sales in the first nine months of 2010 rose 27% to €47.5 billion, EBIT before special item increased 89% to €6.4 billion and EBIT by 127% to €6.1 billion.

For the fourth quarter, the company expects the good business development to continue and has raised its outlook for the current year. For 2010, BASF expects sales of around €63 billion and EBIT before special items of over €8 billion. This exceeds the peak levels of the years 2007 and 2008.

BASF will publish its third-quarter report on Oct. 28.

In spite of the current good results, BASF Chairman Jürgen Hambrecht said he sees a number of uncertainties in the long-term economic outlook.

"The positive economic development of the past months will not necessarily continue at the same pace in 2011. Risks also remain which could jeopardize a sustainable recovery," he said. "The high debt level of many countries threatens the stability of the financial and banking systems. The necessary reduction in government spending and the winding down of national stimulus programs could dampen overall demand."

Risks are also associated with volatile raw material and foreign currency markets, overcapacities, growing geopolitical tensions and protectionism through new trade barriers.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.